Indeed, tumor sensitivity to selective BRAF inhibitors such as vemurafenib was restored after a drug-free period in two patients with BRAFV600E-mutant advanced melanoma who had previously developed disease progression during therapy with selective BRAF inhibition (Seghers, Wilgenhof, Lebbe, & Neyns, 2012). Here, BRAF is linked to neoplasm.